Furthermore, experimental results have confirmed that the sustained in situ activation induced by ZG16 system injection on CD40, along with the role of ZG16 in conjunction with dendritic cells (DCs) to enhance their function, may offer a novel research avenue for immunotherapy targeting pancreatic ductal adenocarcinoma (PDAC). Here, ZG16 is linked to pancreatic ductal adenocarcinoma.